Glancy Binkow & Goldberg LLP announces that it is investigating potential claims against the Board of Directors of Physicians Formula Holdings, Inc. (“Physicians Formula” or the “Company”) (NASDAQ: FACE) related to the sale of the Company to Swander Pace Capital. The transaction is valued at approximately $65 million or $4.25 per share.

This investigation concerns whether the Board of Directors of Physicians Formula breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. At least one analyst has set a target price for the Company’s stock at $5.00 per share.

If you are a shareholder of Physicians Formula, if you have information or would like to learn more about our investigation, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Louis Boyarsky, Esquire, Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067, by telephone at 310-201-9150 or Toll-Free at 888-773-9224 or by email to shareholders@glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Physicians Formula Holdings, Inc. (MM) (NASDAQ:FACE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Physicians Formula Holdings, Inc. (MM) Charts.
Physicians Formula Holdings, Inc. (MM) (NASDAQ:FACE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Physicians Formula Holdings, Inc. (MM) Charts.